Loading...
In 1996, Purdue Pharma launched OxyContin with a bold claim: a time-release formula that made opioid addiction 'extremely rare' — less than 1% risk. Their sales reps handed doctors a landmark 1980 letter to the editor in the New England Journal of Medicine (just five sentences long, studying hospital patients) as proof. Doctors, trusting the FDA-approved label and Purdue's army of 1,000 sales reps, prescribed OxyContin for everything from back pain to dental work. By 2001, OxyContin was a $1 billion drug. But the time-release coating could be crushed, snorted, or dissolved — delivering the full dose instantly. Patients who followed prescriptions developed physical dependence within weeks. When prescriptions ran out or doctors cut them off, patients turned to cheaper alternatives: heroin...
Popular framing: Greedy pharma executives and weak-willed addicts caused the crisis.
Structural analysis: A cobra-effect chain: a tiny letter cited as evidence and FDA labeling created information asymmetry, sales incentives plus pain-as-fifth-vital-sign mandates drove prescriptions, dependence drove demand, and demand pulled in cheaper street alternatives once prescriptions ran out. A reinforcing loop spun across patients, doctors, regulators, and advocacy groups; whoever filled the executive roles, the same mechanism would have produced the same body count.
Focusing on Purdue as the singular cause satisfies the narrative need for a villain but leaves the underlying incentive architecture intact — other manufacturers, the same regulatory framework, and the same fee-for-service prescribing model remain. Without addressing the structural feedback loops, the system will produce analogous crises through different molecules or markets.
